167 related articles for article (PubMed ID: 38264637)
1.
Jones NT; Wagner L; Hahn MCP; Scarlett CO; Wenthur CJ
Front Psychiatry; 2023; 14():1303365. PubMed ID: 38264637
[TBL] [Abstract][Full Text] [Related]
2. Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS.
Zhai W; Li L; Zhao J; Xiang P; Liu M; Shi Y; Dang Y
Drug Test Anal; 2022 Jul; 14(7):1300-1309. PubMed ID: 35312166
[TBL] [Abstract][Full Text] [Related]
3. Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.
Glatfelter GC; Pottie E; Partilla JS; Sherwood AM; Kaylo K; Pham DNK; Naeem M; Sammeta VR; DeBoer S; Golen JA; Hulley EB; Stove CP; Chadeayne AR; Manke DR; Baumann MH
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1181-1196. PubMed ID: 36407948
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR
Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056
[TBL] [Abstract][Full Text] [Related]
5. Bis(4-acet-oxy-
Chadeayne AR; Golen JA; Manke DR
Acta Crystallogr E Crystallogr Commun; 2019 Jun; 75(Pt 6):900-902. PubMed ID: 31391991
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.
Kolaczynska KE; Liechti ME; Duthaler U
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Feb; 1164():122486. PubMed ID: 33485158
[TBL] [Abstract][Full Text] [Related]
7.
Khan FI; Hassan F; Lai D
Front Immunol; 2021; 12():794780. PubMed ID: 35095870
[TBL] [Abstract][Full Text] [Related]
8. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
9. Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders.
Raithatha SA; Hagel JM; Matinkhoo K; Yu L; Press D; Cook SG; Sharma G; Dhananjaya D; Jensen G; Lee JB; Cai C; Gallant J; Bains J; Tucker JE; Facchini PJ
J Med Chem; 2024 Jan; 67(2):1024-1043. PubMed ID: 37983270
[TBL] [Abstract][Full Text] [Related]
10. Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Gomonit MM; Skillman B; Swortwood MJ
J Forensic Sci; 2024 Mar; 69(2):678-687. PubMed ID: 38140718
[TBL] [Abstract][Full Text] [Related]
11. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
Halberstadt AL; Koedood L; Powell SB; Geyer MA
J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
[TBL] [Abstract][Full Text] [Related]
12. Psilocin - The "real deal" or an extraction byproduct.
Gutman O; Tenne D; Bretler U
J Forensic Sci; 2023 Jan; 68(1):327-334. PubMed ID: 36333836
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samples.
Cardoso MS; da Cunha KF; Silva IG; Fiorentin TR; de Campos EG; Costa JL
J Anal Toxicol; 2023 Dec; 47(9):835-841. PubMed ID: 37642343
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis of the antidepressant action of the magic mushroom extract, psilocin.
Hakami Zanjani AA; Nguyen TQT; Jacobsen L; Khandelia H
Biochim Biophys Acta Proteins Proteom; 2023 Jul; 1871(4):140914. PubMed ID: 37019325
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
Dinis-Oliveira RJ
Drug Metab Rev; 2017 Feb; 49(1):84-91. PubMed ID: 28074670
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin.
Dahmane E; Hutson PR; Gobburu JVS
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):78-85. PubMed ID: 32250059
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the Structure-Activity Relationships of Psilocybin Analogues.
Klein AK; Chatha M; Laskowski LJ; Anderson EI; Brandt SD; Chapman SJ; McCorvy JD; Halberstadt AL
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):533-542. PubMed ID: 33860183
[TBL] [Abstract][Full Text] [Related]
19. Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights.
Laabi S; LeMmon C; Vogel C; Chacon M; Jimenez VM
Int Immunopharmacol; 2024 Mar; 130():111753. PubMed ID: 38401463
[TBL] [Abstract][Full Text] [Related]
20. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
